title: Pathological gambling in Parkinson's disease: risk factors and differences from dopamine dysregulation. An analysis of published case series.
abstract: Pathological gambling (PG) has been reported as a complication of the treatment of Parkinson's disease (PD). We examined all published cases of PG for prevalence and risk factors of this complication, the relationship of PG and use of dopamine agonists (DA), and the relationship of PG to the dopamine dysregulation syndrome (DDS). The prevalence of PG in prospective studies of PD patients using DA has been reported between 2.3 and 8%, compared to approximately 1% in the general population. As in the general population, PD patients with this complication are often young, male and have psychiatric co-morbidity. The vast majority are on DA, often at maximum dose or above. Differences between oral DA failed to reach significance. PG associated with levodopa monotherapy is uncommon, but in the majority of cases levodopa is co-prescribed, suggesting possible cross-sensitization of brain systems mediating reward. PG can occur with DDS but often occurs in isolation. In contrast to DDS, escalation and self regulation of anti-parkinsonian medication are not usually seen. PG in patients with PD using DA is higher than PG reported in the general population, but shares similar characteristics and risk factors. PG is predominantly associated with oral DA. It often occurs in isolation and may not be associated with DDS, which typically occurs on treatment with levodopa or subcutaneous apomorphine.
authors.affiliation: Department of Clinical Neurosciences, Royal Free & University College Medical School, London, United Kingdom.
authors.forename: David A
authors.initials: DA
authors.lastname: Gallagher
authors.forename: Sean S
authors.initials: SS
authors.lastname: O'Sullivan
authors.forename: Andrew H
authors.initials: AH
authors.lastname: Evans
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Lees
authors.forename: Anette
authors.initials: A
authors.lastname: Schrag
mesh_terms: D000328:Adult; D000368:Aged; D016009:Chi-Square Distribution; D004298:Dopamine / Q000378:metabolism*; D018491:Dopamine Agonists / Q000009:adverse effects*; D005260:Female; D005715:Gambling; D006801:Humans; D007980:Levodopa / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D010300:Parkinson Disease / Q000188:drug therapy / Q000523:psychology*; D011446:Prospective Studies; D011930:Reaction Time / Q000187:drug effects; D012189:Retrospective Studies; D012307:Risk Factors
chemical_list: D018491:Dopamine Agonists; D007980:Levodopa; D004298:Dopamine